Herbst Kinsky most recently advised ORIGIMM Biotechnology GmbH in the course of the sale of 100% of the shares in the company to Sanofi Foreign Participation B.V. – a wholly owned subsidiary of the French Sanofi S.A. It was agreed not to disclose the transaction volume.

Founded in Austria in 2014, ORIGIMM Biotechnology GmbH is a biotechnology company focused on the discovery of antigens and functional drug targets for the prevention and treatment of infectious diseases and dermatological conditions associated with various microbial species of skin microbiomes. Origimm’s lead program is the development of a vaccine against Propionibacterium acnes (P. acnes) for the prevention and treatment of acne vulgaris. The same product can be used in other indications, e.g. to prevent P. acnes implant-associated infections.

Sanofi is a French pharmaceutical company formed in 2004 by the merger of Sanofi-Synthélabo and Aventis. With 2020 sales of €36.04 billion, Sanofi is one of the largest pharmaceutical companies in the world by revenue. With more than 100,000 employees in 100 countries, Sanofi applies scientific innovation and solutions to healthcare around the globe.

“Transactions like this are what confirm our long-standing commitment to the start-up and venture capital scene. Working with young companies allows us to continuously broaden our horizons. Such success stories inspire not only us, but the entire Austrian biotech scene,” says Philipp Kinsky, partner at Herbst Kinsky.

The team was led by Philipp Kinsky with support from Carl Walderdorff, Philipp Herold and Georg Durstberger.